{"name":"Nanjing Leads Biolabs Co.,Ltd","slug":"nanjing-leads-biolabs-coltd","ticker":"","exchange":"","domain":"nanjingleadsbiolabs.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Axitinib Tablets","genericName":"Axitinib Tablets","slug":"axitinib-tablets","indication":"Advanced renal cell carcinoma","status":"phase_1"},{"name":"Tislelizumab Injection","genericName":"Tislelizumab Injection","slug":"tislelizumab-injection","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"LBL-015 for Injections","genericName":"LBL-015 for Injections","slug":"lbl-015-for-injections","indication":"Other","status":"phase_1"},{"name":"LBL-024 for Injection","genericName":"LBL-024 for Injection","slug":"lbl-024-for-injection","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Axitinib Tablets","genericName":"Axitinib Tablets","slug":"axitinib-tablets","phase":"phase_1","mechanism":"Axitinib is a selective inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3).","indications":["Advanced renal cell carcinoma"],"catalyst":""},{"name":"LBL-015 for Injections","genericName":"LBL-015 for Injections","slug":"lbl-015-for-injections","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LBL-024 for Injection","genericName":"LBL-024 for Injection","slug":"lbl-024-for-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tislelizumab Injection","genericName":"Tislelizumab Injection","slug":"tislelizumab-injection","phase":"phase_3","mechanism":"Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of immune cells, to inhibit the immune system's attack on cancer cells.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic esophageal squamous cell carcinoma","Locally advanced or metastatic urothelial carcinoma","Adenocarcinoma of the stomach","Gastric cancer"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":2,"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}